You just read:

Harvest Technologies Announces FDA Approval of Its Pivotal Randomized, Controlled, Double Blind Multicenter IDE Trial Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia

News provided by

Harvest Technologies Corp.

Mar 22, 2011, 08:15 ET